These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 22069660)

  • 1. Cholera-like enterotoxins and Regulatory T cells.
    Basset C; Thiam F; Martino CD; Holton J; Clements JD; Kohli E
    Toxins (Basel); 2010 Jul; 2(7):1774-95. PubMed ID: 22069660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal and systemic antibody responses after peroral or intranasal immunization: effects of conjugation to enterotoxin B subunits and/or of co-administration with free toxin as adjuvant.
    Rask C; Fredriksson M; Lindblad M; Czerkinsky C; Holmgren J
    APMIS; 2000 Mar; 108(3):178-86. PubMed ID: 10752686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An enzymatically active a domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants.
    Bagley KC; Abdelwahab SF; Tuskan RG; Lewis GK
    Infect Immun; 2003 Dec; 71(12):6850-6. PubMed ID: 14638772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins.
    Connell TD
    Expert Rev Vaccines; 2007 Oct; 6(5):821-34. PubMed ID: 17931161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic.
    Williams NA; Hirst TR; Nashar TO
    Immunol Today; 1999 Feb; 20(2):95-101. PubMed ID: 10098329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins.
    Rappuoli R; Pizza M; Douce G; Dougan G
    Immunol Today; 1999 Nov; 20(11):493-500. PubMed ID: 10529776
    [No Abstract]   [Full Text] [Related]  

  • 7. Cholera toxin and Escherichia coli heat-labile enterotoxin, but not their nontoxic counterparts, improve the antigen-presenting cell function of human B lymphocytes.
    Negri DR; Pinto D; Vendetti S; Patrizio M; Sanchez M; Riccomi A; Ruggiero P; Del Giudice G; De Magistris MT
    Infect Immun; 2009 May; 77(5):1924-35. PubMed ID: 19223474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of the immune response by the cholera-like enterotoxins.
    Plant A; Williams NA
    Curr Top Med Chem; 2004; 4(5):509-19. PubMed ID: 14965302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Type II heat-labile enterotoxins LT-IIa and LT-IIb and their respective B pentamers differentially induce and regulate cytokine production in human monocytic cells.
    Hajishengallis G; Nawar H; Tapping RI; Russell MW; Connell TD
    Infect Immun; 2004 Nov; 72(11):6351-8. PubMed ID: 15501764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Harandi AM; Czerkinsky C
    Expert Rev Vaccines; 2003 Apr; 2(2):205-17. PubMed ID: 12899572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal vaccines based on the use of cholera toxin B subunit as immunogen and antigen carrier.
    Lebens M; Holmgren J
    Dev Biol Stand; 1994; 82():215-27. PubMed ID: 7958476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the reactogenicity, adjuvanticity and antigenicity of LT(R192G) and LT(R192G/L211A) by intradermal immunization in mice.
    Maciel M; Smith M; Poole ST; Laird RM; Rollenhagen JE; Kaminski RW; Wenzel H; Bourgeois AL; Savarino SJ
    PLoS One; 2019; 14(11):e0224073. PubMed ID: 31682624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids.
    Bowman CC; Clements JD
    Infect Immun; 2001 Mar; 69(3):1528-35. PubMed ID: 11179323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.
    Tamura S; Yamanaka A; Shimohara M; Tomita T; Komase K; Tsuda Y; Suzuki Y; Nagamine T; Kawahara K; Danbara H
    Vaccine; 1994 Apr; 12(5):419-26. PubMed ID: 8023550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
    Holmgren J; Bourgeois L; Carlin N; Clements J; Gustafsson B; Lundgren A; Nygren E; Tobias J; Walker R; Svennerholm AM
    Vaccine; 2013 May; 31(20):2457-64. PubMed ID: 23541621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of ADP-ribosylation and G(M1)-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxin.
    de Haan L; Verweij W; Agsteribbe E; Wilschut J
    Immunol Cell Biol; 1998 Jun; 76(3):270-9. PubMed ID: 9682971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
    Tamura SI; Kurata T
    Jpn J Infect Dis; 2000 Jun; 53(3):98-106. PubMed ID: 10957706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of GM1 binding in the mucosal immunogenicity and adjuvant activity of the Escherichia coli heat-labile enterotoxin and its B subunit.
    de Haan L; Verweij WR; Feil IK; Holtrop M; Hol WG; Agsteribbe E; Wilschut J
    Immunology; 1998 Jul; 94(3):424-30. PubMed ID: 9767427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential binding of Escherichia coli enterotoxins LT-IIa and LT-IIb and of cholera toxin elicits differences in apoptosis, proliferation, and activation of lymphoid cells.
    Arce S; Nawar HF; Russell MW; Connell TD
    Infect Immun; 2005 May; 73(5):2718-27. PubMed ID: 15845474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of receptor binding in the immunogenicity, adjuvanticity and therapeutic properties of cholera toxin and Escherichia coli heat-labile enterotoxin.
    Nashar TO; Williams NA; Hirst TR
    Med Microbiol Immunol; 1998 Jun; 187(1):3-10. PubMed ID: 9749977
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.